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Abstract
Background: Cannabis will soon become legalized in Canada, and it is currently unclear how this will impact
public health. Methadone maintenance treatment (MMT) is the most common pharmacological treatment for
opioid use disorder (OUD), and despite its documented effectiveness, a large number of patients respond poorly
and experience relapse to illicit opioids. Some studies implicate cannabis use as a risk factor for poor MMT
response. Although it is well established that substance-use behaviors differ by sex, few of these studies have
considered sex as a potential moderator. The current study aims to investigate sex differences in the association
between cannabis use and illicit opioid use in a cohort of MMT patients.
Methods: This multicentre study recruited participants on MMT for OUD from Canadian Addiction Treatment
Centre sites in Ontario, Canada. Sex differences in the association between any cannabis use and illicit opioid use
were investigated using multivariable logistic regression. A secondary analysis was conducted to investigate the
association with heaviness of cannabis use.
Results: The study included 414 men and 363 women with OUD receiving MMT. Cannabis use was significantly
associated with illicit opioid use in women only (OR = 1.82, 95% CI 1.18, 2.82, p = 0.007). Heaviness of cannabis use
was not associated with illicit opioid use in men or women.
Conclusions: This is the largest study to date examining the association between cannabis use and illicit opioid
use. Cannabis use may be a sex-specific predictor of poor response to MMT, such that women are more likely to
use illicit opioids if they also use cannabis during treatment. Women may show improved treatment outcomes if
cannabis use is addressed during MMT.
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Background
Canada is currently developing legislation for the legalization
of cannabis [1]. The rationale is that legalization would have
social and economic advantages by generating revenue and
deterring such crimes as illegal drug dealing [2]. Prohibition
has been ineffective, with data suggesting that this policy op-
tion has created more societal costs by way of excessive incar-
ceration, largely involving already marginalized individuals
[3], and no evidence to suggest that these criminal penalties
have any substantial effect on public health [4].
Colorado, USA, has recently legalized cannabis, and
while it remains premature to assess the public health im-
pact of this policy, data show that the commercialization
of medical marijuana in 2009 led to a 20% increase in
college age (18–25 years) monthly marijuana use and a
36% increase in adult (26+ years) monthly marijuana use
in the following 3 years [5]. Legalizing cannabis will
almost certainly increase its availability and accessibility;
plausible mechanisms for increasing recreational use
include reduced prices, ease of access, criminal penalties
no longer acting as a deterrent, and increased social ac-
ceptability [6]. It is reasonable to expect that Canada will
observe a similar increase in the prevalence of cannabis
use, though its public health impact remains uncertain.
Despite the commonly held perception that cannabis
is relatively harmless [7], its use has been linked to ad-
verse consequences such as cognitive impairment, lower
life satisfaction, respiratory problems, and increased risk
of developing psychotic episodes and disorders [8].
Those with a history of psychiatric or substance-use dis-
orders can experience worsened symptoms from canna-
bis use [1]. Cannabis users are also at heightened risk for
developing other substance-use disorders [9]. However,
the current system of criminalization is similarly associ-
ated with individual and public risks. For example, indi-
viduals with a criminal record from minor possession
charges often experience considerable difficulties in find-
ing employment or housing leading to further social and
health risks [1]. Public costs of criminalization are also
substantial, with an estimated $2.3 billion spent annually
on enforcement and prosecution [1].
While public health risks of cannabis legalization may
by and large be minimal, certain vulnerable populations
are more susceptible to the deleterious effects of its use.
One such population are those with substance-use disor-
ders. North America is currently in the midst of an
opioid crisis [10], in which we are witnessing a dramatic
increase in non-medical use of opioids and subsequently
the incidence of opioid use disorder (OUD). While
opioid abuse is associated with serious adverse out-
comes, it has been shown that the development of addic-
tion is a major driver in the increase in opioid-related
morbidity and mortality [11], indicating the extent to
which OUD negatively impacts public health.
Because of the ongoing opioid epidemic in Canada, we
must remain mindful of how increasing accessibility of
cannabis will impact this population, in particular. Cur-
rently, the most commonly prescribed treatment for
OUD is methadone maintenance treatment (MMT), an
opioid substitution therapy [12]. MMT has proven to be
effective in retaining patients in treatment and reducing
opioid use and mortality [13], and this effectiveness has
led to a steep increase in patients on MMT. In Ontario,
Canada, the number of patients receiving MMT has
nearly doubled since 2010 [12]. Despite its effectiveness,
a significant number of patients respond poorly to treat-
ment and experience relapse [14]. Illicit opioid use in
combination with MMT is of immense concern, as it is
a substantial risk factor for overdose and death [15].
Recent studies point to a changing landscape of OUD
and those in treatment, one that includes a higher
percentage of women, older aged patients, and more
individuals abusing prescription opioids rather than
heroin [16]. These sociodemographic changes warrant
a re-evaluation of risk factors associated with poor
MMT outcomes.
Compared to the general population, patients on
MMT show a higher prevalence of cannabis use [16],
and because of its documented association with polysub-
stance use [9, 17], psychiatric disorders [18], and overall
worse quality of life [19], represents a potential risk
factor for poor MMT outcomes. Several studies have in-
vestigated the influence of cannabis use on MMT out-
comes in humans, though the results are mixed. Some
studies have indicated cannabis use is associated with
poorer treatment outcomes [20–22] while others looking
at illicit opioid use found no significant association
[23–26]. Although this is the case, confidence in these
diverging results is reduced by methodological limitations
such as small sample size and subjective outcome mea-
sures, making further investigations merited.
Furthermore, few studies have considered sex as a po-
tential moderator. It is well established that substance-
use behaviors differ by sex and different social and
biological factors contribute to the development of
substance-use disorders between men and women [27].
Although a higher proportion of men use cannabis,
women who use cannabis are more likely to experience
adverse outcomes such as development of cannabis use
disorder, and may also be more likely to show negative
outcomes from cannabis in other domains such as more
severe cannabis withdrawal symptoms and [28] and
worse mental health and social functioning [29]. A large
survey of cannabis users, for example, found that a
larger proportion of men use cannabis for recreational
purposes while more women reported using it for pur-
poses of self-medication [30]. Thus, motivational pro-
cesses for drug use may differ between men and women.
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The objective for this study is to investigate sex differ-
ences in the association between cannabis use and illicit
opioid use during methadone maintenance treatment.
We will build on previous research by including a large,
representative sample of MMT patients to ensure
adequate power and generalizability of findings. Our
secondary objective is to determine whether heaviness of
cannabis use is associated with illicit opioid use among
male and female cannabis users.
Methods
Participants and procedure
Data were collected as part of the Genetics of Opioid
Addiction (GENOA) program, an ongoing prospective
cohort study conducted in collaboration with the Popu-
lation Genomics Program at McMaster University, and
the Canadian Addiction Treatment Centre (CATC) [31].
We recruited participants from 16 CATC sites across
Ontario, Canada, from 2013 to 2016. Patients were
eligible for participation if they were ≥18 years old, on
methadone maintenance treatment for OUD, and able to
provide informed written consent. Individuals were
excluded if they did not speak English, were on an opi-
oid substitution therapy other than methadone, or
refused to provide blood or urine samples (Fig. 1). If
individuals were deemed eligible for participation, they
were provided with a written consent form to read and
sign. Eligible participants provided informed written
consent, upon which they underwent a face-to-face
interview administered by trained research staff. Partici-
pants were compensated with a 5$ coffee shop gift card.
This study was approved by the Hamilton Integrated
Research Ethics Board (HIREB; Study ID 11-056).
Data collection
The study participants provided sociodemographic and
clinical information during the face-to-face interview.
Participants were asked to report their biological sex,
and all participants reported either male or female. We
also collected information regarding current methadone
maintenance treatment, methadone dose, duration of
current treatment, and information about any past treat-
ments for opioid use disorder.
The Maudsley Addiction Profile (MAP) [32] was ad-
ministered to retrieve information about substance-use,
health risk behaviors, physical and psychological health,
and personal and social functioning in the past 30 days.
Substance-use data included information on number of
days used in the past 30, typical dose used, and route of
administration. We also used the physical and psy-
chological health sections of the MAP to compare gen-
eral health and well-being among participants. These
Fig. 1 Flow diagram for eligibility and screening of participants
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sections comprised of eight questions each and were
scored using a Likert scale ranging from 0 to 4 (never-
always) to produce a maximum score of 40 per section.
All study data were collected and managed by trained re-
searchers using REDCap electronic data capture tools [33].
Drug use measurements
In addition to self-reported use of drugs using the MAP,
all study participants underwent routine weekly or bi-
weekly urine toxicology screens at the clinical sites part of
routine clinical care as per CATC management protocol.
Cannabis use
Cannabis use, the primary predictor variable, was mea-
sured using urinalysis (cut-off = 50 ng/ml for tetrahydro-
cannabinol) in the past 3 months. Unfortunately, several
clinics discontinued screening for cannabis during urine
testing, so only 45.0% of participants had any cannabis
urine screens. Therefore, we opted to use self-reported
cannabis use from the MAP. To verify the validity of
self-reports, we calculated the sensitivity and specificity
using participants who had data for both urinalysis and
MAP (n = 349). The sensitivity was 79.9% (95% CI 72.7,
85.8) and specificity was 80.0% (95% CI 73.6, 85.4), and
thus we deemed self-reported cannabis use an appropri-
ate measure of cannabis use. Sensitivity and specificity
values did not significantly differ between men and
women, and there were no significant differences be-
tween false negatives and false positives.
For the primary regression analysis, we dichotomized
cannabis use as any reported use versus no use in the
past 30 days for our main predictor variable. We defined
heaviness of cannabis use as the product of number of
days used in the past 30 days by the typical dose per use
(measured in grams) as reported on the MAP.
To quantify cannabis heaviness for participants who
reported doses in values other than grams, we utilized the
quantification of common “marijuana measurements” as
determined and reported by Mariani et al. [34]. Many
participants reported values such as “less than one joint”
or “couple of puffs of a joint”, and we coded all of these
reports as equivalent to one half of a joint (0.33 g). For all
other reported quantities, we consulted an addiction
expert to estimate the average dose per route of adminis-
tration based on clinical experience. We used the follow-
ing quantifications: bowl = 0.25 g and cookie = 2 g.
Illicit opioid use
Illicit opioid use during MMT was the primary outcome
which was measured in the 3 months prior to baseline
interview using urinalysis, with participants averaging 16
screens per 3 months. The cut-off concentration was
300 ng/mL for opiates and 100 ng/mL for oxycodone.
We dichotomized illicit opioid use to reflect no positive
screens versus any positive screens during a 3-month
duration. This dichotomized variable is a patient-important
treatment outcome, as the ultimate goal of MMT is
complete abstinence of opioids. Individuals were ex-
cluded from analysis if they were currently prescribed
any opioid medications, as these compromise the re-
sults of urine screens.
Statistical analysis
Descriptive statistics were reported to compare demo-
graphic characteristics between men and women. Con-
tinuous variables were expressed as mean (standard
deviation) and categorical variables were expressed as
number (percent). We employed a Student’s t test to test
significant differences between continuous variables, and
a chi-square test for categorical variables.
A multivariable logistic regression analysis was per-
formed to investigate the association between cannabis
and illicit opioid use, including an interaction term, sex
by cannabis use, to investigate between-group sex differ-
ences. In the analysis, we controlled for age, sex, metha-
done dose, and treatment duration. Two multivariable
logistic regression analyses were also performed for men
and women separately to investigate within-group sex
differences, controlling for the same covariates.
We conducted a secondary analysis on cannabis users
to determine whether it is only the presence of cannabis
use that influences treatment outcome or the heaviness
of use that drives the association. For this, we replaced
the binary cannabis variable with the continuous meas-
urement of cannabis use heaviness. Multivariable logistic
regression analyses were employed for male and fe-
male users, controlling for the same covariates as in
the initial analysis.
Variables were assessed for collinearity using the vari-
ance inflation factor (VIF), and variables with VIF > 10
were excluded from the analysis. Adjusted odds ratios
(OR), 95% confidence intervals (CI), and p values gener-
ated from the regression models are reported. The level of
significance for hypothesis testing was set at alpha = 0.05
for the main analysis and alpha = 0.025 for analyses per-
formed separately on men and women.
The general requirement for logistic regression is to have
a minimum of 10 events per predictor variable [35]. We
included 212 men and 183 women with the event (presence
of at least one positive opioid urine screen), and we in-
cluded four predictor variables therefore the study was
adequately powered for analysis. When isolating cannabis
users for the secondary analysis, there were 133 men and
91 women with the event, demonstrating adequate power.
All analyses were performed using IBM SPSS version
20. This study is reported in adherence to the Stre-
ngthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines [36].
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Results
Participants’ characteristics
The total sample comprised of 777 participants inc-
luding 414 men and 363 women (Fig. 1). Ages varied
from 18 to 65 years with a mean age of 38.05 years
(SD =11.11). The mean daily methadone dose was
75.44 mg (SD = 45.84), and the average duration of
current MMT was 48.55 months (SD = 49.53).
Demographic and clinical characteristics comparing
men and women are reported in Table 1. 59.7 of males
and 43.5% of females reported using cannabis. Further-
more, men on average used cannabis more often in the
past 30 days and at a higher average dose. Women also
had significantly worse physical and psychological func-
tioning compared to men. A comparison of cannabis
users and non-users can be found in Appendix 1.
Cannabis use
The primary logistic regression analysis did not yield a
significant association between cannabis use and illicit
opioid use, after adjusting for age, sex, methadone dose,
and treatment duration (OR = 1.16, 95% CI 0.77, 1.75,
p = 0.49). The interaction of sex and cannabis use also
did not show a significant association with illicit opioid
use in the regression model (OR = 1.52, 95% CI 0.84,
2.77, p = 0.17) (Table 2).
Sex differences
After adjusting for age, methadone dose, and treatment
duration, any cannabis use in the past 30 days was sig-
nificantly associated with illicit opioid use (OR = 1.82,
95% CI 1.18, 2.82, p = 0.007) in women but not in men
(OR = 1.11, 95% CI 0.73, 1.69, p = 0.62) (Table 3).
Heaviness of cannabis use
Among cannabis users, the mean number of days of
cannabis use in the past 30 days was 18.91 days
(SD = 12.46) and the mean daily dose was 1.31 g
(SD = 1.50), varying from 0.10 to 14.00 g. The logistic
regression analysis showed the heaviness of cannabis use
to be unrelated to illicit opioid use in both women
(OR = 1.00, 95% CI 0.99, 1.01, p = 0.92) and men
(OR = 1.01, 95% CI 1.00–1.01, p = 0.07) (Table 4).
Discussion
The current study sought to investigate sex dif-
ferences in the association between cannabis use and
illicit opioid use in a cohort of MMT patients. Our
results suggest that cannabis use during treatment
may be a predictor of illicit opioid use in women.
This could help explain why previous studies inves-
tigating this relationship provided conflicting results
due to the lack of consideration of sex effect on the
Table 1 Demographic and clinical characteristics of men and women on MMT
Variable Men (n = 414) Women (n = 363) p value
Age in years (SD) 39.07 (11.72) 36.88 (10.27) 0.006
Ethnicity (% Caucasian) 347 (84.6%) 288 (80.2%) 0.127
Marital status
Never married (%) 203 (49.0%) 158 (43.5%) 0.079
Married/common law/living with partner (%) 129 (31.2%) 109 (30.0%)
Widowed/separated/divorced (%) 82 (19.8%) 96 (26.4%)
Education
Less than grade 9 (%) 88 (21.4%) 68 (18.9%) 0.008
Grade 9–12 (%) 233 (56.6%) 177 (49.2%)
Trade school, college, university (%) 91 (22.1%) 115 (31.9%)
Employment (% currently working) 175 (42.3%) 98 (27.0%) <0.001
Smoking status (% current smoker) 336 (81.2%) 320 (88.2%) 0.007
Age of onset of opioid use in years (SD) 24.90 (8.90) 25.00 (8.11) 0.881
Methadone dose in mg/day (SD) 78.15 (48.36) 72.34 (42.63) 0.079
Current treatment duration in years (SD) 4.10 (4.11) 3.98 (4.15) 0.704
Physical functioning (SD) 14.45 (7.74) 16.79 (7.38) <0.001
Psychological functioning (SD) 12.33 (8.82) 15.11 (9.36) <0.001
Cannabis use (% cannabis users) 247 (59.7%) 158 (43.5%) <0.001
Days cannabis use in last 30 (SD) 11.97 (13.54) 7.44 (12.02) <0.001
Average cannabis dose in g/day (SD) 1.48 (1.71) 1.04 (1.03) 0.004
Maximum score for the MAP physical and psychological functioning is 40, with higher scores indicating worse functioning
SD standard deviation
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association between cannabis use and continued opioid
use in MMT [23, 37].
To our knowledge, this is the largest study conducted
to date investigating the relationship between cannabis
use and illicit opioid use in men and women on MMT.
While some studies have indicated that cannabis use
is associated with poor MMT treatment outcomes
[20–22], several previous studies looking at illicit opi-
oid use have not found significant results [23, 24, 26].
These inconsistent reports could be explained by meth-
odological limitations such as the selection of the study
participants [23] and insufficient investigations into sex
differences in cannabis use and MMT treatment out-
comes. For example, the external validity of the studies
reporting no association may be low, as two were se-
condary analyses of RCTs with restrictive inclusion criteria
[23, 26], and one study analyzed a sample of predomin-
antly men [24]. In this case, it is unlikely these findings
apply to a current sample of MMT patients which contain
about 50% women.
Despite the well-documented sex differences in the socio-
demographic and clinical profiles of patients in MMT [38],
there has been little research conducted on sex-
specific predictors of MMT outcomes. Women are
more sensitive to the subjective effects of cannabis
(i.e., subjective ratings of intoxication and other drug
effects like altered mood and sociability) and con-
sequently show a faster trajectory to cannabis use
disorder [28], indicating they may be have a higher
proclivity to problematic cannabis use. Furthermore,
cannabis use has consistently been shown to be associ-
ated with worse mental health outcomes in women
compared to men [19, 39].
Preclinical research points to many important de-
velopmental and biological sex differences which
suggest females are more susceptible to the deleteri-
ous effects of cannabis use. Studies in rodents have
found that females exposed to Δ9-tetrahydrocanna-
binol (THC) were more susceptible to the reinfor-
cing effects of cannabinoids, such that female rats
more quickly acquired self-administration and were
more sensitive to drug- and cue-induced reinstate-
ment of the drug [40]. These behavioral observations
may be explained by the findings that prolonged ex-
posure to THC led to a much greater cannabinoid
receptor desensitization in female rats compared to
their male counterparts [40]. It was also found sig-
nificantly greater concentrations of THC and its
metabolites in the female rat brain compared to
males [41]. Despite this evidence, there is a paucity
of research looking into the sexually dimorphic ef-
fects of cannabis in humans [42].
While there is reason to consider biological mecha-
nisms as explanation for the differential consequences of
cannabis use in men and women, other clinical and
social factors should not be overlooked. Women in
MMT tend to show a higher prevalence of comorbid
psychiatric and physical illnesses [16, 43, 44], as well as
more severe opioid craving upon treatment entry [45]
which may represent confounding factors that serve to
increase rates of both cannabis and opioid use during
MMT. As such, these patients may have motivation to
use both drugs for purposes of self-medication. Indeed a
survey of cannabis users found men were more likely to
use cannabis recreationally while women were more
likely to use it for purposes of self-medication for condi-
tions such as anxiety and headaches [30]. As we only
classified participants based on biological sex, further
work should evaluate gender constructs and their influ-
ence on treatment response to determine whether the
observed sex differences can be explained by biological
or social mechanisms, or a combination of the two.
Table 2 Multivariable logistic regression analysis on predictors
of illicit opioid use
Predictor Odds ratio 95% CI p value
Cannabis use 1.16 0.77–1.75 0.485
Sex*cannabis use 1.52 0.84–2.77 0.169
Age 1.00 0.99–1.02 0.857
Sex 0.83 0.54–1.28 0.399
Methadone dose 0.96* 0.93–0.99 0.023
Duration of treatment 0.91* 0.87–0.95 <0.001
Age and duration of treatment interpreted as a one-point increase. Methadone
dose interpreted as a 10-point increase
*Significant at p < 0.05
OR odds ratio, CI confidence interval
Table 3 Multivariable logistic regression analysis on predictors of illicit opioid use by sex
Men Women
Predictor Odds ratio 95% CI p value Odds ratio 95% CI p value
Cannabis use 1.11 0.73–1.69 0.618 1.82* 1.18–2.82 0.007
Age 0.99 0.98–1.01 0.588 1.01 0.99–1.03 0.356
Methadone dose 0.94* 0.90–0.99 0.010 0.99 0.94–1.04 0.634
Duration of treatment 0.92* 0.87–0.97 0.004 0.90* 0. 84–0.95 <0.001
Age and duration of treatment interpreted as a one-point increase. Methadone dose interpreted as a ten-point increase
OR odds ratio, CI confidence interval
*Significant at p < 0.025
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Unexpectedly, when looking at cannabis users only, we
failed to find an association between heaviness of canna-
bis use and illicit opioid use in either sex. It is currently
unclear why this is the case. A study by Saxon et al. [46]
found that MMT patients who had intermittent positive
cannabis urine screens had a significantly higher per-
centage of positive screens for other drugs of abuse
compared to those who consistently had positive
screens. Thus, the relationship between cannabis use
heaviness and illicit opioid use may not be linear.
On the other hand, this observation may simply be
the result of our rough approximation of cannabis
use heaviness and slang terminology reported in the
interviews, rather than reflecting the true effect.
Several studies also indicate a distinct difference be-
tween recreational cannabis users and those with
cannabis use disorder, regardless of frequency of use,
such that patients with a cannabis use disorder actually
show less polysubstance use during MMT [23, 47, 48]. It
is unclear why this is the case, but it may represent a
confounding effect such as having cannabis use dis-
order may be associated with lack of means to obtain
further drugs and lack of will or time to use other drugs
while on MMT. In this study, we did not find a signifi-
cant association between the amount or frequency of
cannabis use and illicit opioid use. However, our study
lacks the ability to distinguish cannabis use disorder
from recreational use.
Another consideration is to account for the potency
of cannabis used by patients, which was not measured
in this study. Research on opioid-dependent rats sug-
gests cannabidiol (CBD) and THC, the two main
active ingredients in cannabis, actually generate oppos-
ing response. Administration of CBD extinguishes cue-
induced heroin-seeking behaviors following periods of
abstinence [49], whereas THC administration seems to
heighten opioid sensitivity and increase heroin self-
administration [50, 51]. This antagonism is further
supported by imaging studies in humans, which suggest
that CBD attenuates the neurotoxic and adverse psy-
chiatric effects of THC [52, 53]. Because of these differen-
tial effects, those who use cannabis for medicinal purposes
may choose higher CBD concentrations while those
who use it for recreational purposes may prefer
greater amounts of THC. Therefore, depending on ra-
tio of CBD to THC in the ingested cannabis, an indi-
vidual may become more or less susceptible to further
drug use, and this distinction should be investigated
further.
Some limitations of this study should be noted. The
cross-sectional nature of the analysis prevents any
causal inferences from being made. Self-reported can-
nabis use, despite its adequate sensitivity and specifi-
city may also be a biased estimate. Particularly in
chronic cannabis users, short-term memory and recall
may be impaired [54, 55] which could affect the ac-
curacy of retrospective self-reports even further. Con-
versely, there is evidence to suggest self-report use
may be a more valid and sensitive indicator of canna-
bis use compared to urine screening. For example,
patients enrolled in methadone maintenance treat-
ment are required to provide urine samples at least
one or two times per week; however, studies have
shown the average time for the first negative result in
urine screening for THC metabolites following a sin-
gle dose of THC was 8.5 days following ingestion for
infrequent users and 19.1 days for chronic users [56].
This suggests that urine data may overestimate the
frequency of cannabis use.
Conclusions
This study suggests that cannabis use is a potential
sex-specific predictor of poor outcome during MMT.
It will be important to look at the impact of cannabis
use on women by systematically screening for canna-
bis use in women with OUD and providing addiction
counseling to address not only opioid use but also
cannabis use in this vulnerable group. This study also
showed that women with OUD experienced physical
and psychological symptoms more frequently than
men; these symptoms may be the underlying cause of
cannabis use in women in this study and addiction
services should consider sex-specific treatment pro-
grams to manage symptoms and co-substance use.
Table 4 Multivariable logistic regression analysis on predictors of illicit opioid use among cannabis users by sex
Men Women
Predictor Odds ratio 95% CI p value Odds ratio 95% CI p value
Cannabis use heaviness 1.01 1.00–1.01 0.072 1.00 0.99–1.01 0.917
Age 0.99 0.97–1.02 0.476 1.02 0.98–1.05 0.449
Methadone dose 0.92* 0.87–0.98 0.016 1.02 0.94–1.11 0.662
Duration of treatment 0.91 0.84–0.99 0.037 0.91 0.83–0.99 0.035
Cannabis use heaviness, age, and duration of treatment interpreted as a one-point increase. Methadone dose interpreted as a 10-point increase
*Significant at p < 0.025
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